KPTI Insider Trading Activity and SEC Form 4 Filings
KPTI insider trading summary
Over the past 12 months, insiders at Karyopharm Therapeutics Inc. (KPTI) reported 16 sales worth $105K by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $105K.
Latest KPTI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 16, 2026 | Kristin Abate | Chief Accounting Officer | Sell | $2K (4,788 @ $0.34) |
| Oct 1, 2026 | Kristin Abate | Chief Accounting Officer | Sell | $450 (378 @ $1.19) |
| Sep 1, 2026 | Kristin Abate | Chief Accounting Officer | Sell | $38 (19 @ $2.02) |
| Jul 28, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sell | $1K (189 @ $7.10) |
| May 14, 2026 | Kristin Abate | Chief Accounting Officer | Sell | $504 (53 @ $9.50) |
| May 14, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sell | $4K (403 @ $9.50) |
| May 14, 2026 | Michael Mano | EVP, CLO&Secretary | Sell | $3K (266 @ $9.50) |
| May 14, 2026 | Richard A. Paulson | President and CEO | Sell | $21K (2,203 @ $9.50) |
| May 14, 2026 | Reshma Rangwala | EVP & Chief Medical Officer | Sell | $4K (408 @ $9.50) |
| May 14, 2026 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Sell | $3K (324 @ $9.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.